Form D · Biotechnology
Revalia Bio, Inc.
New Haven, CT · CIK 0002043834
Offering snapshot reported Nov 6, 2024 · SEC filing
- Reported sold
- $12.3M Offering amount: $17M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 25, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 6, 2024 | Initial | $12,294,616 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528748
Source: Form D, filed Nov 6, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Milad Alucozai | Director |
| Gregory T. Tietjen | Director, Executive |
| Brian Wilcove | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
55 Church Street #400
New Haven, CT, 06510
New Haven, CT, 06510